Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05327686
Title Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NRG Oncology
Indications

renal cell carcinoma

Therapies

Axitinib + Pembrolizumab

Lenvatinib + Pembrolizumab

Ipilimumab + Nivolumab

Avelumab + Axitinib

Cabozantinib + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.